Hartaj Singh
Stock Analyst at Oppenheimer
(1.70)
# 3,389
Out of 5,097 analysts
108
Total ratings
45.54%
Success rate
-8.29%
Average return
Main Sectors:
Stocks Rated by Hartaj Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $30 → $37 | $21.23 | +74.28% | 13 | Jul 29, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $925 → $900 | $779.36 | +15.48% | 15 | Apr 29, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $132 → $125 | $124.16 | +0.68% | 15 | Apr 25, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Perform | n/a | $460.31 | - | 17 | Dec 19, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Perform | n/a | $82.82 | - | 6 | Dec 11, 2024 | |
| ATXS Astria Therapeutics | Maintains: Outperform | $26 → $28 | $12.93 | +116.61% | 6 | Nov 14, 2024 | |
| UTHR United Therapeutics | Maintains: Outperform | $575 → $600 | $513.79 | +16.78% | 7 | Oct 31, 2024 | |
| MRNA Moderna | Downgrades: Perform | n/a | $34.90 | - | 8 | Sep 13, 2024 | |
| CLLS Cellectis | Maintains: Outperform | $11 → $10 | $4.69 | +113.22% | 5 | Jun 12, 2024 | |
| BMEA Biomea Fusion | Maintains: Outperform | $70 → $60 | $1.33 | +4,411.28% | 5 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $3.19 | +182.13% | 4 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $2.25 | +1,677.78% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $10.62 | +107.16% | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $650 | $2.64 | +24,521.21% | 1 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $30 | $18.15 | +65.29% | 1 | Jan 26, 2018 |
Sarepta Therapeutics
Jul 29, 2025
Upgrades: Outperform
Price Target: $30 → $37
Current: $21.23
Upside: +74.28%
Regeneron Pharmaceuticals
Apr 29, 2025
Maintains: Outperform
Price Target: $925 → $900
Current: $779.36
Upside: +15.48%
Gilead Sciences
Apr 25, 2025
Maintains: Outperform
Price Target: $132 → $125
Current: $124.16
Upside: +0.68%
Vertex Pharmaceuticals
Dec 19, 2024
Downgrades: Perform
Price Target: n/a
Current: $460.31
Upside: -
Spruce Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $82.82
Upside: -
Astria Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $26 → $28
Current: $12.93
Upside: +116.61%
United Therapeutics
Oct 31, 2024
Maintains: Outperform
Price Target: $575 → $600
Current: $513.79
Upside: +16.78%
Moderna
Sep 13, 2024
Downgrades: Perform
Price Target: n/a
Current: $34.90
Upside: -
Cellectis
Jun 12, 2024
Maintains: Outperform
Price Target: $11 → $10
Current: $4.69
Upside: +113.22%
Biomea Fusion
May 30, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $1.33
Upside: +4,411.28%
Apr 23, 2024
Maintains: Outperform
Price Target: $9
Current: $3.19
Upside: +182.13%
Mar 8, 2024
Maintains: Outperform
Price Target: $40
Current: $2.25
Upside: +1,677.78%
Jan 5, 2024
Initiates: Outperform
Price Target: $22
Current: $10.62
Upside: +107.16%
Nov 1, 2018
Initiates: Outperform
Price Target: $650
Current: $2.64
Upside: +24,521.21%
Jan 26, 2018
Maintains: Outperform
Price Target: $24 → $30
Current: $18.15
Upside: +65.29%